Literature DB >> 19337270

Tocilizumab.

Clemens Scheinecker, Josef Smolen, Uma Yasothan, Jeffrey Stoll, Peter Kirkpatrick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19337270     DOI： 10.1038/nrd2863

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  12 in total

Review 1.  New therapies for treatment of rheumatoid arthritis.

Authors:  Josef S Smolen; Daniel Aletaha; Marcus Koeller; Michael H Weisman; Paul Emery
Journal:  Lancet       Date:  2007-12-01       Impact factor: 79.321

Review 2.  Interleukin 6: from bench to bedside.

Authors:  Norihiro Nishimoto; Tadamitsu Kishimoto
Journal:  Nat Clin Pract Rheumatol       Date:  2006-11

3.  Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity.

Authors:  R Madhok; A Crilly; J Watson; H A Capell
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

4.  Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.

Authors:  Mark C Genovese; James D McKay; Evgeny L Nasonov; Eduardo F Mysler; Nilzio A da Silva; Emma Alecock; Thasia Woodworth; Juan J Gomez-Reino
Journal:  Arthritis Rheum       Date:  2008-10

5.  Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

Authors:  Josef S Smolen; Andre Beaulieu; Andrea Rubbert-Roth; Cesar Ramos-Remus; Josef Rovensky; Emma Alecock; Thasia Woodworth; Rieke Alten
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

6.  Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis.

Authors:  N Takagi; M Mihara; Y Moriya; N Nishimoto; K Yoshizaki; T Kishimoto; Y Takeda; Y Ohsugi
Journal:  Arthritis Rheum       Date:  1998-12

7.  Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade.

Authors:  J S Smolen; C Han; D M F M van der Heijde; P Emery; J M Bathon; E Keystone; R N Maini; J R Kalden; D Aletaha; D Baker; J Han; M Bala; E W St Clair
Journal:  Ann Rheum Dis       Date:  2008-07-01       Impact factor: 19.103

8.  Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth.

Authors:  K Sato; M Tsuchiya; J Saldanha; Y Koishihara; Y Ohsugi; T Kishimoto; M M Bendig
Journal:  Cancer Res       Date:  1993-02-15       Impact factor: 12.701

9.  Assessing remission in clinical practice.

Authors:  M Mierau; M Schoels; G Gonda; J Fuchs; D Aletaha; J S Smolen
Journal:  Rheumatology (Oxford)       Date:  2007-03-06       Impact factor: 7.580

10.  Interleukin 6 is required for the development of collagen-induced arthritis.

Authors:  T Alonzi; E Fattori; D Lazzaro; P Costa; L Probert; G Kollias; F De Benedetti; V Poli; G Ciliberto
Journal:  J Exp Med       Date:  1998-02-16       Impact factor: 14.307
View more
  12 in total

1.  Biopharmaceutical benchmarks 2010.

Authors:  Gary Walsh
Journal:  Nat Biotechnol       Date:  2010-09       Impact factor: 54.908

2.  Deal watch : BMS acquires rights for IL-6 inhibitor.

Authors: 
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

Review 3.  Rheumatoid arthritis: a role for immunosenescence?

Authors:  Tamsin M Lindstrom; William H Robinson
Journal:  J Am Geriatr Soc       Date:  2010-07-19       Impact factor: 5.562

4.  IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.

Authors:  Mauricio S Caetano; Huiyuan Zhang; Amber M Cumpian; Lei Gong; Nese Unver; Edwin J Ostrin; Soudabeh Daliri; Seon Hee Chang; Cesar E Ochoa; Samir Hanash; Carmen Behrens; Ignacio I Wistuba; Cinthya Sternberg; Humam Kadara; Carlos Gil Ferreira; Stephanie S Watowich; Seyed Javad Moghaddam
Journal:  Cancer Res       Date:  2016-04-01       Impact factor: 12.701

Review 5.  Tocilizumab.

Authors:  Adith Venkiteshwaran
Journal:  MAbs       Date:  2009-09-10       Impact factor: 5.857

Review 6.  Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.

Authors:  M Pizzi; M Boi; F Bertoni; G Inghirami
Journal:  Leukemia       Date:  2016-06-08       Impact factor: 11.528

7.  Genome-wide association study of circulating interleukin 6 levels identifies novel loci.

Authors:  Tarunveer S Ahluwalia; Bram P Prins; Mohammadreza Abdollahi; Nicola J Armstrong; Stella Aslibekyan; Lisa Bain; Barbara Jefferis; Jens Baumert; Marian Beekman; Yoav Ben-Shlomo; Joshua C Bis; Braxton D Mitchell; Eco de Geus; Graciela E Delgado; Diana Marek; Joel Eriksson; Eero Kajantie; Stavroula Kanoni; John P Kemp; Chen Lu; Riccardo E Marioni; Stela McLachlan; Yuri Milaneschi; Ilja M Nolte; Alexandros M Petrelis; Eleonora Porcu; Maria Sabater-Lleal; Elnaz Naderi; Ilkka Seppälä; Tina Shah; Gaurav Singhal; Marie Standl; Alexander Teumer; Anbupalam Thalamuthu; Elisabeth Thiering; Stella Trompet; Christie M Ballantyne; Emelia J Benjamin; Juan P Casas; Catherine Toben; George Dedoussis; Joris Deelen; Peter Durda; Jorgen Engmann; Mary F Feitosa; Harald Grallert; Ann Hammarstedt; Sarah E Harris; Georg Homuth; Jouke-Jan Hottenga; Sirpa Jalkanen; Yalda Jamshidi; Magdalene C Jawahar; Tine Jess; Mika Kivimaki; Marcus E Kleber; Jari Lahti; Yongmei Liu; Pedro Marques-Vidal; Dan Mellström; Simon P Mooijaart; Martina Müller-Nurasyid; Brenda Penninx; Joana A Revez; Peter Rossing; Katri Räikkönen; Naveed Sattar; Hubert Scharnagl; Bengt Sennblad; Angela Silveira; Beate St Pourcain; Nicholas J Timpson; Julian Trollor; Jenny van Dongen; Diana Van Heemst; Sophie Visvikis-Siest; Peter Vollenweider; Uwe Völker; Melanie Waldenberger; Gonneke Willemsen; Delilah Zabaneh; Richard W Morris; Donna K Arnett; Bernhard T Baune; Dorret I Boomsma; Yen-Pei C Chang; Ian J Deary; Panos Deloukas; Johan G Eriksson; David M Evans; Manuel A Ferreira; Tom Gaunt; Vilmundur Gudnason; Anders Hamsten; Joachim Heinrich; Aroon Hingorani; Steve E Humphries; J Wouter Jukema; Wolfgang Koenig; Meena Kumari; Zoltan Kutalik; Deborah A Lawlor; Terho Lehtimäki; Winfried März; Karen A Mather; Silvia Naitza; Matthias Nauck; Claes Ohlsson; Jackie F Price; Olli Raitakari; Ken Rice; Perminder S Sachdev; Eline Slagboom; Thorkild I A Sørensen; Tim Spector; David Stacey; Maria G Stathopoulou; Toshiko Tanaka; S Goya Wannamethee; Peter Whincup; Jerome I Rotter; Abbas Dehghan; Eric Boerwinkle; Bruce M Psaty; Harold Snieder; Behrooz Z Alizadeh
Journal:  Hum Mol Genet       Date:  2021-04-27       Impact factor: 6.150

8.  LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor.

Authors:  Peter G K Clark; Lucas C C Vieira; Cynthia Tallant; Oleg Fedorov; Dean C Singleton; Catherine M Rogers; Octovia P Monteiro; James M Bennett; Roberta Baronio; Susanne Müller; Danette L Daniels; Jacqui Méndez; Stefan Knapp; Paul E Brennan; Darren J Dixon
Journal:  Angew Chem Int Ed Engl       Date:  2015-04-13       Impact factor: 15.336

Review 9.  Trial Watch: Immunostimulatory cytokines.

Authors:  Erika Vacchelli; Alexander Eggermont; Wolf Hervé Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-05-07       Impact factor: 8.110

10.  LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor.

Authors:  Peter G K Clark; Lucas C C Vieira; Cynthia Tallant; Oleg Fedorov; Dean C Singleton; Catherine M Rogers; Octovia P Monteiro; James M Bennett; Roberta Baronio; Susanne Müller; Danette L Daniels; Jacqui Méndez; Stefan Knapp; Paul E Brennan; Darren J Dixon
Journal:  Angew Chem Weinheim Bergstr Ger       Date:  2015-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.